A bold return marks Carolyn Bertozzi’s rejoiner to Eli Lilly’s board of directors
Eli Lilly and Company announced on December 8, 2025, that Carolyn R. Bertozzi, Ph.D., will rejoin the company’s board and will serve on the Science and Technology as well as the Ethics and Compliance committees.
David A. Ricks, Lilly’s chair and CEO, welcomed Bertozzi back to the board, highlighting her Nobel Prize-winning achievements in chemistry. Her work has reshaped how targeted medicines are developed, with a notable impact on cancer therapies. As Lilly continues to push forward with innovative oncology and immunology strategies, her insight is expected to be highly valuable in guiding breakthrough medicines to patients.
Dr. Bertozzi currently holds multiple prestigious roles, including the Baker Family Director of Sarafan ChEM-H and Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences at Stanford University. She is also a Professor by courtesy of Chemical and Systems Biology and Radiology and serves as an Investigator with the Howard Hughes Medical Institute.
Her research career has earned numerous honors, and she is an elected member of the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. Bertozzi previously served on Lilly’s board from 2017 to 2021.
About Lilly
Lilly is a pharmaceutical company dedicated to turning scientific discoveries into therapies that improve lives worldwide. With nearly 150 years of history, Lilly’s medicines now help tens of millions of people across the globe. By leveraging biotechnology, chemistry, and genetic medicine, its scientists pursue new breakthroughs in several areas: redefining diabetes care; addressing obesity and its long-term effects; advancing treatments for Alzheimer’s disease; offering solutions for challenging immune system disorders; and transforming difficult-to-treat cancers into manageable conditions.
Lilly emphasizes making life better by developing innovative clinical trials that reflect the world’s diversity and by striving to ensure medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow the company on Facebook, Instagram, and LinkedIn.
Forward-looking statements
This release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, relating to research and related initiatives and reflecting Lilly’s current beliefs and expectations. The development, manufacturing, and commercialization of pharmaceutical products involve substantial risks and uncertainties that could cause actual results to differ, including factors affecting costs, timing, capacity, personnel, and other elements related to expansion and initiatives. For additional risks and uncertainties, see Lilly’s Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly does not undertake any duty to update forward-looking statements.
SOURCE Eli Lilly and Company
